Standout Papers

Toxicity and response criteria of the Eastern Cooperative Oncology Group 1982 2026 1996 2011 8.6k
  1. Toxicity and response criteria of the Eastern Cooperative Oncology Group (1982)
    Martin M. Oken, Richard H. Creech et al. American Journal of Clinical Oncology
  2. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (2017)
    David Cameron, Martine Piccart et al. The Lancet

Immediate Impact

2 by Nobel laureates 3 from Science/Nature 56 standout
Sub-graph 1 of 21

Citing Papers

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
2023 Standout
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
2023 Standout

Works of Eleanor McFadden being referenced

Toxicity and response criteria of the Eastern Cooperative Oncology Group
1982 Standout

Author Peers

Author Last Decade Papers Cites
Eleanor McFadden 4907 1130 304 3139 2089 13 9.9k
Richard H. Creech 5206 1088 256 3662 2147 43 10.5k
Martin Krapcho 3526 855 298 1964 1239 14 7.9k
William T. McGivney 5926 862 439 4485 3004 28 12.5k
Milton P. Eisner 3457 839 248 1866 1229 9 7.8k
Marie‐Josèphe Horner 3530 848 264 1850 1278 26 7.9k
M. C. Pike 2866 1207 235 2153 1814 33 9.9k
B. Miller 3550 852 263 1872 1221 6 7.9k
Kerri McPherson 2201 972 230 1697 1614 25 8.2k
Matt Hayat 3229 845 247 1841 1206 6 7.7k
Limin X. Clegg 6474 1671 789 3567 2552 43 16.1k

All Works

Loading papers...

Rankless by CCL
2026